Lanreotide: Uses, Mechanism, Evidence, and Side Effects

Patients managing acromegaly or certain neuroendocrine tumors often want to know how their treatment works and what the evidence actually supports. Lanreotide is an established option in this space, with decades of clinical use behind its approval.

Key takeaways

• Lanreotide is a somatostatin analog marketed as Lanreotide Acetate.
• It is approved for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome.
• More than 120 clinical trials have studied lanreotide across its approved and investigational uses.
• Commonly reported adverse events include diarrhoea, fatigue, nausea, and injection site pain.
• The label does not carry a boxed warning.

What Lanreotide Is

Lanreotide is an octapeptide analog of natural somatostatin, a hormone the body uses to regulate growth hormone and other secretions. Its mechanism of action is believed to work similarly to natural somatostatin, helping to reduce excess hormone activity. It carries the PubChem identifier CID 6918011.

What Lanreotide Is Approved For

Lanreotide Injection, sold as Lanreotide Acetate, is approved for three main uses. It treats acromegaly in patients who have not responded adequately to, or cannot undergo, surgery or radiotherapy. It is also approved for adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs, where it aims to improve progression-free survival. The third approved use is for adults with carcinoid syndrome, where lanreotide reduces how often patients need short-acting somatostatin analog rescue therapy. The label does not include a boxed warning.

What the Evidence Shows

Lanreotide has been studied in 124 registered clinical trials. One phase 3 trial compared Lanreotide Autogel to Sandostatin LAR Depot for managing carcinoid syndrome symptoms, though it was terminated. A separate phase 2/3 trial completed enrollment to examine growth hormone, IGF-I, and somatostatin analogues in hepatocellular carcinoma, an area outside the drug's core approved indications.

Reported Side Effects

Reports submitted to FAERS describe a pattern dominated by gastrointestinal and general symptoms. Diarrhoea (1,415 reports) and nausea (725) were among the most frequently cited, alongside fatigue (972) and abdominal pain (568). Injection site pain (596) and headache (502) were also commonly reported, along with a substantial number of off-label use reports (1,461) and death reports (1,221). These figures represent report counts submitted to a passive surveillance system, not confirmed incidence or causation.